Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share. This is a 40.91 percent decrease over losses of $(0.44) per share from the same period last year.
Related Posts
Deutsche Bank Maintains Buy on Qualcomm, Raises Price Target to $210
Deutsche Bank analyst Ross Seymore maintains Qualcomm (NASDAQ:QCOM) with a Buy and raises the price target from $190 to $210.
Mark Zuckerberg’s Sister Randi Says Dogecoin Killer Shiba Inu Has Become Mainstream
In a recent video Randi Zuckerberg, the sister of Mark Zuckerberg, the CEO of Meta Platform
Enanta Pharmaceuticals To Present New Data For EDP-235, Its 3CL Protease Inhibitor, In Development As An Oral, Once-Daily Treatment For COVID-19, At The 36th International Conference On Antiviral Research
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease